

Attorney's Docket No.: 07039-119001

OFFICIAL COMMUNICATION

FACSIMILE

FOR THE PERSONAL ATTENTION OF:

EXAMINER A. HOLLERAN

FAX RECEIVED

OCT 16 2002

GROUP 1600

GROUP 1642 FAX NO: 703-872-9306

Number of pages including this page 8

OFFICIAL

Applicant : Svetomir N. Markovic
Serial No. : 09/187,385
Filed : November 6, 1998

Art Unit : 1642
Examiner : A. Holleran

FACSIMILE COMMUNICATION

Title : INTERFERON IMMUNOTHERAPY


Commissioner for Patents
Washington, DC 20231

Madam:

Attached to this facsimile communication cover sheet is an Amendment and Response,
faxed this 15th day of October, 2002, to Group 1642, the United States Patent and Trademark
Office.

Respectfully submitted,

Date: October 15, 2002


Monica McCormick Graham, Ph.D.
Reg. No. 42,600

Fish & Richardson P.C., P.A.
60 South Sixth Street
Suite 3300
Minneapolis, MN 55402
Telephone: (612) 335-5070
Fax: (612) 288-9696

60109596.doc

NOTE: This facsimile is intended for the addressee only and may contain privileged or confidential information. If you have received this facsimile in error, please immediately call us collect at (612) 335-5070 to arrange for its return. Thank you.

Received from <612 288 9713> at 10/15/02 3:47:29 PM [Eastern Daylight Time]

Amended E/#17
10-23-02
002

Attorney's Docket No.: 07039-119001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Svetomir N. Markovic
Serial No. : 09/187,385
Filed : November 6, 1998
Title : INTERFERON IMMUNOTHERAPY

Art Unit : 1642
Examiner : A. Holleran

Commissioner for Patents
Washington, DC 20231

AMENDMENT AND RESPONSE

In response to the action mailed July 16, 2002, please amend the application as follows:

In the claims:

Please cancel claims 4-6, 28-29, and 39-40.

Please amend claims 26 and 27 as follows:

-- 26. (Four times amended) A method for stimulating the immune system of a human patient having a non-resectable malignant tumor, said method comprising

a) determining the natural killer lymphocyte cytotoxicity of said patient to provide a baseline natural killer lymphocyte cytotoxicity;

b) administering an immunostimulatory dosage of an α -interferon composition to said patient, wherein said immunostimulatory dosage is 500,000 U/m² or less per day and at least about 250,000 U/m² per day; and

c) treating said patient with effective non-surgical medical methodologies to diminish said tumor.

27. (Amended) A method for stimulating the immune system of a human patient having a resectable malignant tumor, said method comprising:

CERTIFICATE OF TRANSMISSION BY FACSIMILE

I hereby certify that this correspondence is being transmitted by facsimile to the Patent and Trademark Office on the date indicated below.

Date of Transmission October 15, 2002
Signature Kathryn J. Sanderson
Typed or Printed Name of Person Signing Certificate
Kathryn J. Sanderson